RedHill Biopharma launches trial of combination therapy for prostate cancer
Israeli pharmaceutical company RedHill Biopharma has initiated a placebo-controlled Phase II trial to assess the combination of opaganib and darolutamide…
Oncology
-
-
Imvax secures $29m to support Phase IIb glioblastoma therapy trial
Imvax has received $29m in a financing round from current investors, aimed at advancing the Phase IIb trial of its…
-
Pfizer reports positive outcomes from trial of mCRC combination therapy
Pfizer has reported positive outcomes from the Phase III BREAKWATER trial of BRAFTOVI plus cetuximab and mFOLFOX6 for treating metastatic…
-
Genprex doses first subject in expansion part of lung cancer gene therapy trial
Genprex has dosed the first subject in the Phase II expansion portion of its Acclaim-3 trial of the Reqorsa gene…
-
FDA grants ODD status to Zai Lab’s lung cancer treatment
The US Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Zai Lab’s delta-like ligand 3 (DLL3)…
-
German PEI approves enrolment in cohort 5 of Oncolytics’ pancreatic cancer trial
The Paul-Ehrlich-Institute (PEI) in Germany has granted approval to continue subject enrolment in cohort 5 of Oncolytics Biotech’s GOBLET trial,…
-
Pfizer’s Phase III bladder cancer therapy trial meets primary endpoint
Pfizer's Phase III CREST trial evaluating sasanlimab with Bacillus Calmette-Guérin (BCG), as induction treatment with or without maintenance in subjects…
-
Sanofi reports positive results from trial of multiple myeloma drug candidate
French pharmaceutical company Sanofi has reported results from its Phase III IRAKLIA trial, which evaluated Sarclisa (isatuximab) as a potential…
-
Samsung Biologics and LigaChem extend ADC services deal
Samsung Biologics has extended its collaboration with LigaChem Biosciences for antibody-drug conjugate (ADC) services. The partnership will leverage Samsung Biologics'…
-
Chugai and Araris enter $780m ADC research collaboration
Chugai Pharmaceutical and Araris Biotech have entered an antibody-drug conjugate (ADC)-focused research collaboration and option-to-license agreement worth up to $780m.…
